IN VIVO SCREENING ASSAYS
First Claim
1. A method for identifying an inhibitor of LOXL2 activity, the method comprising treating animals with a test molecule, wherein the animals comprise one or more areas of fibrosis, and wherein a test molecule that ameliorates symptoms of fibrosis is identified as an inhibitor of LOXL2 activity.
2 Assignments
0 Petitions
Accused Products
Abstract
Disclosed herein are methods for identifying inhibitors of LOXL2 activity using in vivo assays. The assays include, for example, CCL4-induced liver fibrosis, bleomycin-induced lung fibrosis, collagen-induced arthritis, tumor growth following surgical orthotopic implantation of cultured tumor cells, metastasis following intracardiac injection of cultured tumor cells, tumor xenograft models, and vasculogenesis and/or angiogenesis following implantation of exogenous basement membrane.
-
Citations
22 Claims
- 1. A method for identifying an inhibitor of LOXL2 activity, the method comprising treating animals with a test molecule, wherein the animals comprise one or more areas of fibrosis, and wherein a test molecule that ameliorates symptoms of fibrosis is identified as an inhibitor of LOXL2 activity.
- 6. A method for identifying an inhibitor of LOXL2 activity, the method comprising treating animals with a test molecule, wherein the animals comprise one or more areas of arthritis, and wherein a test molecule that ameliorates symptoms of arthritis is identified as an inhibitor of LOXL2 activity.
- 8. A method for identifying an inhibitor of LOXL2 activity, the method comprising treating animals with a test molecule, wherein the animals comprise one or more experimental tumors generated by surgical orthotopic implantation of tumor cells, and wherein a test molecule that reduces tumor volume is identified as an inhibitor of LOXL2 activity.
- 11. A method for identifying an inhibitor of LOXL2 activity, the method comprising treating animals with a test molecule, wherein the animals comprise experimental metastases generated by intravascular injection of tumor cells, and wherein a test molecule that reduces the degree of metastasis is identified as an inhibitor of LOXL2 activity.
- 13. A method for identifying an inhibitor of LOXL2 activity, the method comprising treating animals with a test molecule, wherein the animals comprise an exogenous basement membrane, and wherein a test molecule that reduces vasculogenesis of the exogenous basement membrane is identified as an inhibitor of LOXL2 activity.
- 15. A method for identifying an inhibitor of LOXL2 activity, the method comprising treating animals with a test molecule, wherein the animals comprise one or more areas of desmoplasia, and wherein a test molecule that ameliorates symptoms of desmoplasia is identified as an inhibitor of LOXL2 activity.
Specification